Skip to main content

Table 1 Characteristics, methodological quality, treatment employed and outcome of the trials

From: The correlates of benefit from neoadjuvant chemotherapy before surgery in non-small-cell lung cancer: a metaregression analysis

Trial Reference Recruitment period Publication year Trial size Origin of study Randomization method Stratification criteria Trial type Stage Fraction with squamous cell (%) Details of neoadjuvant treatment HRa(95% CI)
Dautzenberg et al. 10 1985 to 1987 1990 26 European No details given Not reported Full text Stage 1 to 3 81 VCP × 2 1.10 (0.41 to 2.93)
Roth et al. 13,14 1987 to 1993 1998 60 US No details given Not reported Full text Stage 3 only 37 CEP × 3 0.56 (0.31 to 1.01)
Rosell et al. 11, 12 1989 to 1991 1999 60 European Details given Not reported Full text Stage 3 only 70 MIP × 3 0.50 (0.30 to 0.85)
Zhou et al. 21 1990 to 2001 2001 624 Asian Details given Not reported Full text Stage 3 only 51 BAI/MVP/CAP/EP/VIP/GP/NP/PC/TN × 2 0.87 (0.71 to 1.07)
De Pierre et al. 15 1991 to 1997 2002 355 European No details given Reported Full text Stage 1 to 3 74 MIP × 2 0.83 (0.64 to 1.07)
JCOG 16 1993 to 1998 2003 62 Asian No details given Reported Full text Stage 3 only 24 VP × 3 1.19 (0.69 to 2.05)
Li et al. 24 1990 to 1995 2003 137 Asian No details given Not reported Full text Stage 3 only 80 CAP/EP × 1 0.68 (0.46 to 1.00)
Liao et al. 22 1995 to 1997 2003 211 Asian Details given Reported Full text Stage 1 to 3 - MVP/MAP × 2 1.06 (0.76 to 1.48)
Yao et al. 23 1990 to 2002 2004 456 Asian Details given Not reported Full text Stage 3 only 55 GP/NP/MVP/EP × 2 0.83 (0.67 to 1.03)
Sorensen et al. 17 1998 to 2004 2005 90 US No details given Not reported Abstract Stage 1 to 3 - TP × 3 0.91 (0.55 to 1.50)
s9900 18,19 1999 to 2004 2006 336 European No details given Not reported Full text Stage 1 to 3 38 PC × 3 0.79 (0.60 to 1.06)
MRCLU22 6 1997 to 2005 2007 519 European No details given Not reported Full text Stage 1 to 3 49 MVP/MIP/NP/PC/DC/GP × 3 1.02 (0.80 to 1.31)
Ch.E.S.T 20, 25 2000 to 2004 2008 270 European No details given Not reported Abstract Stage 1 to 3 41 GP × 3 0.63 (0.46 to 0.87)
Felip et al. 26 2000 to 2007 2010 409b European No details given Not reported Full text Stage 1 to 3 52 PC × 3 0.96 (0.84 to 1.10)
  1. aHazard ratio for mortality.
  2. bNumber of cases in surgery only, and neoadjuvant chemotherapy arms; excludes patients in the adjuvant chemotherapy arm.
  3. BAI = bronchial artery infusion; CAP = cyclophosphamide, adriamycin, cisplatin; CEP = etoposide, cyclophosphamide, cisplatin; DC = docetaxel, carboplatin; EP = etoposide, cisplatin; GP = gemcitabine, cisplatin; MAP = mitomycin, adriamycin, cisplatin; MIP = mitomycin, ifosfamide, cisplatin; MVP = mitomycin, vindesine, cisplatin; NP = navelbine, cisplatin; PC = paclitaxel, carboplatin; TN = paclitaxel, navelbine; VCP = vindesine, cyclophosphamide, cisplatin; VIP = vindesine, ifosfamide, cisplatin; VP = vindesine, cisplatin.